Company intelligence / Profile preview

Forward Therapeutics

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Forward Therapeutics is advancing a pipeline of next-generation small molecule immune therapies targeting chronic inflammatory disorders. Its lead program targets TNF-alpha and is currently in preclinical development. The company recently raised $50 million in Series A financing to support advancement toward clinical trials. No clinical results have been reported yet.

Therapeutic areas: Immunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

FT2109

3 more assets in the full pipeline.

Partnerships

Curie.Bio (venture partner supporting operational model and launch)

Beyond the preview

Go deeper on Forward Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forward Therapeutics.